Ouabain
- ouabain
- G-Strophanthin
- Ouabaine
- Gratus strophanthin
- Ouabagenin L-rhamnoside
- Create:2005-06-24
- Modify:2025-01-18
- Acocantherin
- Acolongifloroside K
- G Strophanthin
- G-Strophanthin
- Ouabain
- ouabain
- G-Strophanthin
- Ouabaine
- Gratus strophanthin
- Ouabagenin L-rhamnoside
- Oubain
- Purostrophan
- Acocantherin
- Ouabain anhydrous
- 630-60-4
- Astrobain
- Gratibain
- Strophoperm
- Acocantherine
- Ouabagenin-L-rhamnosid
- Strophalen
- Strodival
- Uabaina
- Ouabain octahydrate
- Rectobaina
- Solufantina
- Strophosan
- G-Strophicor
- Strophantin-g
- CHEBI:472805
- NSC-25485
- Uabanin
- MLS000069786
- CHEMBL222863
- DTXSID0043765
- 5ACL011P69
- Quabain
- SMR000058492
- Strophanthin-G
- 3-(alpha-L-rhamnopyranosyloxy)-1beta,5beta,11alpha,14,19-pentahydroxy-5beta-card-20(22)-enolide
- Card-20(22)-enolide, 3-[(6-deoxy-.alpha.-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxy-, (1.beta.,3.beta.,5.beta.,11.alpha.)-
- OBN
- Ouabain, Octahydrate
- DTXCID8023765
- G-STROPHANTHIN [JAN]
- Cardiac glycoside
- 4-[(1S,2R,3R,5S,7S,10R,11S,14R,15R,17R)-3,7,11,17-tetrahydroxy-2-(hydroxymethyl)-15-methyl-5-{[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]-2,5-dihydrofuran-2-one
- CAS-630-60-4
- Ouabagenin-L-rhamnosid [German]
- SR-01000076047
- CCRIS 965
- UNII-5ACL011P69
- HSDB 3519
- 1ibg
- NCGC00163473-01
- 3-[(1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
- CARD-20(22)-ENOLIDE, 3-((6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)OXY)-1,5,11,14,19-PENTAHYDROXY-, (1.BETA.,3.BETA.,5.BETA.,11.ALPHA.)-
- C29H44O12.8H2O
- EINECS 211-139-3
- NSC 25485
- BRN 0101712
- 3a3y
- Opera_ID_395
- OUABAIN [MI]
- OUABAIN [MART.]
- Prestwick0_000471
- Prestwick1_000471
- Prestwick2_000471
- Prestwick3_000471
- OUABAIN [WHO-DD]
- Epitope ID:161502
- O 3125
- G-STROPHANTHIN [MI]
- Lopac0_000943
- SCHEMBL15433
- BSPBio_000602
- 5-18-05-00625 (Beilstein Handbook Reference)
- Card-20(22)-enolide, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-1,5,11,14,19-pentahydroxy-, (1beta,3beta,5beta,11alpha)-
- SPBio_002541
- OUABAIN [EP MONOGRAPH]
- BPBio1_000664
- cid_439501
- GTPL4826
- OUABAIN ANHYDROUS [HSDB]
- REGID_for_CID_439501
- 3n23
- HMS2089J19
- HMS2235A07
- HMS3262N08
- Tox21_110024
- Tox21_112057
- Tox21_301547
- Tox21_500943
- BDBM50286739
- HB1140
- AKOS024285581
- Tox21_112057_1
- CCG-205024
- CCG-208243
- DB01092
- LP00943
- SDCCGSBI-0050917.P002
- 3-((6-Deoxy-alpha-L-mannopyranosyl)oxy)-1,5,11alpha,14,19-pentahydroxycard-20(22)-enolide
- 3-(6-Deoxy-alpha-L-mannopyranosyloxy)-1,5,11a,14,19-pentahydroxycard-20(22)-enolide
- SMP1_000142
- NCGC00013319-01
- NCGC00015769-02
- NCGC00015769-13
- NCGC00015769-17
- NCGC00015769-30
- NCGC00015769-32
- NCGC00017394-02
- NCGC00017394-07
- NCGC00017394-11
- NCGC00255970-01
- NCGC00261628-01
- NCGC00263656-01
- 3-[(1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
- EU-0100943
- NS00003260
- C01443
- EN300-19631221
- Q285911
- SR-01000721848
- SR-01000076047-1
- SR-01000076047-5
- SR-01000721848-2
- SR-01000721848-4
- BRD-K35708212-331-03-1
- 3-[(6-Deoxy-alpha-L-mannopyranosyl)oxy]-1,5,11alpha,14,19-pentahydoxycard-20(22)-enolide
- (1.BETA.,3.BETA.,5.BETA.,11.ALPHA.)-3-((6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)OXY)-1,5,11,14,19-PENTAHYDROXYCARD-20(22)-ENOLIDE
- (1alpha,3beta,5beta,11alpha,17alpha)-3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxycard-20(22)-enolide
- 3-[(6-Deoxy-.alpha.-L-mannopyranosyl)oxy]-1,5,11.alpha.,14,19-pentahydroxycard-20(22)-enolide
- 4-((1R,3S,5S,8R,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one
- 4-((1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one
- 4-((1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one
- 4-((1R,3S,5S,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one
- 4-[(1R,3aS,3bR,5aS,7S,9R,9aR,9bS,10R,11aR)-3a,5a,9,10-tetrahydroxy-9a-(hydroxymethyl)-11a-methyl-7-{[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]-2,5-dihydrofuran-2-one
- 4-[(1R,3S,5S,10R,11R,13R,14S,17R)-1,5,11,14-Tetrahydroxy-10-hydroxymethyl-13-methyl-3-((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-hexadecahydro-cyclopenta[a]phenanthren-17-yl]-5H-furan-2-one
- 4-[(R)-1,5,11,14-Tetrahydroxy-10-hydroxymethyl-13-methyl-3-(3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-hexadecahydro-cyclopenta[a]phenanthren-17-yl]-5H-furan-2-one
- 4-[1,5,11,14-Tetrahydroxy-10-hydroxymethyl-13-methyl-3-(3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-hexadecahydro-cyclopenta[a]phenanthren-17-yl]-5H-furan-2-one
- 4-[1,5,11,14-Tetrahydroxy-10-hydroxymethyl-13-methyl-3-(3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-hexadecahydro-cyclopenta[a]phenanthren-17-yl]-5H-furan-2-one(Ouabain)
- Ouabain4-[1,5,11,14-Tetrahydroxy-10-hydroxymethyl-13-methyl-3-(3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-hexadecahydro-cyclopenta[a]phenanthren-17-yl]-5H-furan-2-one
228.35 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
244.36 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
241.61 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
129.0699 100
91.0544 78.90
105.0699 59.49
141.0701 59.01
117.0699 55.45
385.2009 100
355.1903 91.69
367.1903 82.68
337.1797 79.78
373.2008 78.78
585.2913 999
586.2946 295
439.2333 226
403.212 146
421.2226 67
403.2101 999
439.2311 775
385.1996 773
373.1996 731
355.1892 470
371.184629 0.27
419.205413 0.15
437.215332 0.13
353.17413 0.12
401.194548 0.06
- Extracellular
- Membrane
Use (kg; approx.) in Germany (2009): >10
Consumption (g per capita; approx.) in Germany (2009): 0.000122
Calculated removal (%): 45.4
H301 (97.6%): Toxic if swallowed [Danger Acute toxicity, oral]
H331 (100%): Toxic if inhaled [Danger Acute toxicity, inhalation]
H373 (97.6%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]
P260, P261, P264, P270, P271, P301+P316, P304+P340, P316, P319, P321, P330, P403+P233, P405, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
Aggregated GHS information provided per 41 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
Acute Tox. 3 (97.6%)
Acute Tox. 3 (100%)
STOT RE 2 (97.6%)
Acute toxicity - category 3
Acute toxicity - category 3
Specific target organ toxicity (repeated exposure) - category 2
Warning: Effects may be delayed up to 12 hours. Caution is advised. Vital signs should be monitored closely.
Signs and Symptoms of Ouabain Exposure: Acute ouabain exposure may produce the following signs and symptoms: nausea, vomiting, headache, lethargy, drowsiness, confusion, slowed pulse, varying degrees of heart block, and heart arrhythmias. Coma, respiratory failure, and heart failure may also occur.
Emergency Life-Support Procedures: Acute exposure to ouabain may require decontamination and life support for the victims. Emergency personnel should wear protective clothing appropriate to the type and degree of contamination. Air-purifying or supplied-air respiratory equipment should also be worn, as necessary. Rescue vehicles should carry supplies such as plastic sheeting and disposable plastic bags to assist in preventing spread of contamination.
Inhalation Exposure:
1. Move victims to fresh air. Emergency personnel should avoid self-exposure to ouabain.
2. Evaluate vital signs including pulse and respiratory rate, and note any trauma. If no pulse is detected, provide CPR. If not breathing, provide artificial respiration. If breathing is labored, administer oxygen or other respiratory support.
3. Obtain authorization and/or further instructions from the local hospital for administration of an antidote or performance of other invasive procedures.
4. Transport to a health care facility.
Dermal/Eye Exposure:
1. Remove victims from exposure. Emergency personnel should avoid self-exposure to ouabain.
2. Evaluate vital signs including pulse and respiratory rate, and note any trauma. If no pulse is detected, provide CPR. If not breathing, provide artificial respiration. If breathing is labored, administer oxygen or other respiratory support.
3. Remove and isolate contaminated clothing as soon as possible.
4. If eye exposure has occurred, eyes must be flushed with lukewarm water for at least 15 minutes.
5. Wash exposed skin areas thoroughly with water.
6. Obtain authorization and/or further instructions from the local hospital for administration of an antidote or performance of other invasive procedures.
7. Transport to a health care facility.
Ingestion Exposure:
1. Evaluate vital signs including pulse and respiratory rate, and note any trauma. If no pulse is detected, provide CPR. If not breathing, provide artificial respiration. If breathing is labored, administer oxygen or other respiratory support.
2. Obtain authorization and/or further instructions from the local hospital for administration of an antidote or performance of other invasive procedures.
3. Vomiting may be induced with syrup of Ipecac. If elapsed time since ingestion of ouabain is unknown or suspected to be greater than 30 minutes, do not induce vomiting and proceed to Step
4. Ipecac should not be administered to children under 6 months of age. Warning: Ingestion of ouabain may result in sudden onset of seizures or loss of consciousness. Syrup of Ipecac should be administered only if victims are alert, have an active gag-reflex, and show no signs of impending seizure or coma. If ANY uncertainty exists, proceed to Step
4. The following dosages of Ipecac are recommended: children up to 1 year old, 10 mL (1/3 oz); children 1 to 12 years old, 15 mL (1/2 oz); adults, 30 mL (1 oz). Ambulate (walk) the victims and give large quantities of water. If vomiting has not occurred after 15 minutes, Ipecac may be readministered. Continue to ambulate and give water to the victims. If vomiting has not occurred within 15 minutes after second administration of Ipecac, administer activated charcoal.
4. Activated charcoal may be administered if victims are conscious and alert. Use 15 to 30 g (1/2 to 1 oz) for children, 50 to 100 g (1-3/4 to 3-1/2 oz) for adults, with 125 to 250 mL (1/2 to 1 cup) of water.
5. Promote excretion by administering a saline cathartic or sorbitol to conscious and alert victims. Children require 15 to 30 g (1/2 to 1 oz) of cathartic; 50 to 100 g (1-3/4 to 3-1/2 oz) is recommended for adults.
6. Transport to a health care facility. (EPA, 1998)
(Non-Specific -- Medicine, n.o.s.) Cool containers that are exposed to flames with water from the side until well after fire is out. For massive fires use unmanned hose holder or monitor nozzles; if this is impossible, withdraw and let fire burn. Wear self-contained (positive pressure if available) breathing apparatus and full protective clothing.
(Non-Specific -- Medicine, n.o.s.) For small fires, use dry chemical, carbon dioxide, water spray, or foam. For large fires, use water spray, fog, or foam. (EPA, 1998)
Excerpt from ERG Guide 151 [Substances - Toxic (Non-Combustible)]:
IMMEDIATE PRECAUTIONARY MEASURE: Isolate spill or leak area in all directions for at least 50 meters (150 feet) for liquids and at least 25 meters (75 feet) for solids.
SPILL: Increase the immediate precautionary measure distance, in the downwind direction, as necessary.
FIRE: If tank, rail tank car or highway tank is involved in a fire, ISOLATE for 800 meters (1/2 mile) in all directions; also, consider initial evacuation for 800 meters (1/2 mile) in all directions. (ERG, 2024)
(Non-Specific -- Medcines, n.o.s.) Keep unnecessary people away; isolate hazard area and deny entry. Stay upwind; keep out of low areas. If water pollution occurs, notify appropriate authorities. Shut off ignition sources; no flares, smoking or flames in hazard area. Keep combustibles (wood, paper, oil, etc.) away from spilled material. Do not touch spilled material.
Small spills: absorb with sand or other noncombustible absorbent material and place into containers for later disposal.
Small dry spills: with clean shovel place material into clean, dry container and cover; move container from spill area.
Large spills: dike far ahead of spill for later disposal. (EPA, 1998)
Alcohols and Polyols
Esters, Sulfate Esters, Phosphate Esters, Thiophosphate Esters, and Borate Esters
Ethers
Hydrocarbons, Aliphatic Unsaturated
Patents are available for this chemical structure:
https://patentscope.wipo.int/search/en/result.jsf?inchikey=LPMXVESGRSUGHW-HBYQJFLCSA-N
- BindingDBLICENSEAll data curated by BindingDB staff are provided under the Creative Commons Attribution 3.0 License (https://creativecommons.org/licenses/by/3.0/us/).https://www.bindingdb.org/rwd/bind/info.jsp4-((1R,3S,5S,8R,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-onehttps://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50286739
- Comparative Toxicogenomics Database (CTD)LICENSEIt is to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of NC State University.http://ctdbase.org/about/legal.jspCardiac Glycosideshttps://ctdbase.org/detail.go?type=chem&acc=D002301
- DrugBankLICENSECreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)https://www.drugbank.ca/legal/terms_of_use
- Therapeutic Target Database (TTD)Acocantherinhttps://idrblab.net/ttd/data/drug/details/D0AR3JAcocantherinhttps://idrblab.net/ttd/data/drug/details/D0PG7V
- Toxin and Toxin Target Database (T3DB)LICENSET3DB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (T3DB) and the original publication.http://www.t3db.ca/downloads
- CAMEO ChemicalsLICENSECAMEO Chemicals and all other CAMEO products are available at no charge to those organizations and individuals (recipients) responsible for the safe handling of chemicals. However, some of the chemical data itself is subject to the copyright restrictions of the companies or organizations that provided the data.https://cameochemicals.noaa.gov/help/reference/terms_and_conditions.htm?d_f=falseCAMEO Chemical Reactivity Classificationhttps://cameochemicals.noaa.gov/browse/react
- CAS Common ChemistryLICENSEThe data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc/4.0/
- ChemIDplusChemIDplus Chemical Information Classificationhttps://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
- EPA Chemicals under the TSCACard-20(22)-enolide, 3-[(6-deoxy-.alpha.-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxy-, (1.beta.,3.beta.,5.beta.,11.alpha.)-https://www.epa.gov/chemicals-under-tscaEPA TSCA Classificationhttps://www.epa.gov/tsca-inventory
- EPA DSSToxCompTox Chemicals Dashboard Chemical Listshttps://comptox.epa.gov/dashboard/chemical-lists/
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-notice3-(6-deoxy-α-L-mannopyranosyloxy)-1,5,11a,14,19-pentahydroxycard-20(22)-enolidehttps://echa.europa.eu/substance-information/-/substanceinfo/100.010.1283-(6-deoxy-α-L-mannopyranosyloxy)-1,5,11a,14,19-pentahydroxycard-20(22)-enolide (EC: 211-139-3)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/45350
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Hazardous Substances Data Bank (HSDB)
- Human Metabolome Database (HMDB)LICENSEHMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.http://www.hmdb.ca/citingHMDB0015224_msms_2226251https://hmdb.ca/metabolites/HMDB0015224#spectra
- New Zealand Environmental Protection Authority (EPA)LICENSEThis work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International licence.https://www.epa.govt.nz/about-this-site/general-copyright-statement/
- NJDOH RTK Hazardous Substance List
- ChEBI
- LOTUS - the natural products occurrence databaseLICENSEThe code for LOTUS is released under the GNU General Public License v3.0.https://lotus.nprod.net/LOTUS Treehttps://lotus.naturalproducts.net/
- Open TargetsLICENSEDatasets generated by the Open Targets Platform are freely available for download.https://platform-docs.opentargets.org/licence
- CCSbaseCCSbase Classificationhttps://ccsbase.net/
- ChEMBLLICENSEAccess to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).http://www.ebi.ac.uk/Information/termsofuse.htmlChEMBL Protein Target Treehttps://www.ebi.ac.uk/chembl/g/#browse/targets
- Hazardous Chemical Information System (HCIS), Safe Work Australia
- Regulation (EC) No 1272/2008 of the European Parliament and of the CouncilLICENSEThe copyright for the editorial content of this source, the summaries of EU legislation and the consolidated texts, which is owned by the EU, is licensed under the Creative Commons Attribution 4.0 International licence.https://eur-lex.europa.eu/content/legal-notice/legal-notice.html
- MassBank of North America (MoNA)LICENSEThe content of the MoNA database is licensed under CC BY 4.0.https://mona.fiehnlab.ucdavis.edu/documentation/license
- NORMAN Suspect List ExchangeLICENSEData: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0https://creativecommons.org/licenses/by/4.0/OUABAINNORMAN Suspect List Exchange Classificationhttps://www.norman-network.com/nds/SLE/
- NIST Mass Spectrometry Data CenterLICENSEData covered by the Standard Reference Data Act of 1968 as amended.https://www.nist.gov/srd/public-law
- Japan Chemical Substance Dictionary (Nikkaji)
- KEGGLICENSEAcademic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial licensehttps://www.kegg.jp/kegg/legal.htmlCompounds with biological roleshttp://www.genome.jp/kegg-bin/get_htext?br08001.kegPhytochemical compoundshttp://www.genome.jp/kegg-bin/get_htext?br08003.kegNatural toxinshttp://www.genome.jp/kegg-bin/get_htext?br08009.keg
- LIPID MAPSLipid Classificationhttps://www.lipidmaps.org/
- Natural Product Activity and Species Source (NPASS)
- MassBank Europe
- Metabolomics Workbench
- Nature Chemical Biology
- PharmGKBLICENSEPharmGKB data are subject to the Creative Commons Attribution-ShareALike 4.0 license (https://creativecommons.org/licenses/by-sa/4.0/).https://www.pharmgkb.org/page/policies
- PharosLICENSEData accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution.https://pharos.nih.gov/about
- Protein Data Bank in Europe (PDBe)
- RCSB Protein Data Bank (RCSB PDB)LICENSEData files contained in the PDB archive (ftp://ftp.wwpdb.org) are free of all copyright restrictions and made fully and freely available for both non-commercial and commercial use. Users of the data should attribute the original authors of that structural data.https://www.rcsb.org/pages/policies
- SpectraBaseOUABAIN,(3-BETA-O-ALPHA-L-RHAMNOSID,5-BETA-OH,11-ALPHA-OH)https://spectrabase.com/spectrum/IHCx1hY3hcs
- Springer Nature
- WHO Anatomical Therapeutic Chemical (ATC) ClassificationLICENSEUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.https://www.whocc.no/copyright_disclaimer/G-strophanthinhttps://www.whocc.no/atc_ddd_index/?code=C01AC01
- Wikidata
- Wikipedia
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmlCardiotonic Agentshttps://www.ncbi.nlm.nih.gov/mesh/68002316Enzyme Inhibitorshttps://www.ncbi.nlm.nih.gov/mesh/68004791
- PubChem
- GHS Classification (UNECE)GHS Classification Treehttp://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
- MolGenieMolGenie Organic Chemistry Ontologyhttps://github.com/MolGenie/ontology/
- PATENTSCOPE (WIPO)SID 403034496https://pubchem.ncbi.nlm.nih.gov/substance/403034496
- NCBI